Revel Pharmaceuticals Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Revel Pharmaceuticals Inc. - overview
Established
2019
Location
San Francisco, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2019 by CEO Aaron Cravens, and Nicholas A. Delateur, Revel Pharmaceuticals Inc. operates as a developer of therapeutics for chronic diseases of aging like osteoarthritis, cardiovascular disease, diabetes, and more. In February 2022, Revel Pharmaceuticals Inc.
raised USD 5. 75 million in seed funding co-led by KIZOO Technology Ventures and Starbloom Capital, with participation from Tubus LLC. Revel Pharmaceuticals develops biotechnology therapeutic enzymes that help in degrading age-associated molecule damage, which is caused by different diseases of aging, such as cardiovascular disease, kidney disease, osteoarthritis, complications of diabetes, and skin aging. The company plans to use its proceeds from March 2022 funding to further the expansion of its enzymatic repair pipeline and crosslink-breakers.
Current Investors
KIZOO Technology Ventures, Tubus Management, Starbloom Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.revelpharmaceuticals.com
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.